RxDoctor Payments Data

Godwin Maduka, MD

Interventional Pain Medicine · Las Vegas, NVNPI 1548363583

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Medtronic at 39.3% of the total. Reporting peaked in 2019 at $1,684 and has fallen 68.6% since, to $529 in 2025.

$4,464in general payments, 2019–2025

Across 166 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Nevro Corp.$1K
  • Curonix LLC$314
  • Forte Bio-pharma LLC$274
  • Stimwave Technologies Incorporated$234
  • Boston Scientific$231
  • plus $399 from 4 others

What the payments were for

  • Travel & lodging$2666%
  • Food & beverage$4,16793%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,464 in reported general payments places this provider in the 55th percentile of 32 interventional pain medicine providers in Nevada.

See all interventional pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$166,586
Medicare patients
459
Services billed
2,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen106$3,210
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen126$2,690
Lidocaine24$2,458
Gabapentin110$875
Oxycodone Hcl44$721
Pregabalin27$531
Tizanidine Hcl86$364
Ibuprofen37$234
Cyclobenzaprine Hcl24$215
Tramadol Hcl20$212
Baclofen21$156
Methocarbamol24$146
Meloxicam26$64

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →